Core Insights - The recent ASCO GU conference presented results from the LITESPARK-011 trial, which evaluated the combination of belzutifan and Lenvima in second-line renal cell carcinoma (RCC) [1] - The trial demonstrated a progression-free survival (PFS) benefit, although it did not show a statistically significant survival benefit at the second interim analysis [1] Industry Dynamics - The discussion centers around the positioning of the belzutifan and Lenvima regimen in the treatment landscape for second-line RCC, particularly in comparison to cabozantinib [1]